Castle Biosciences (CSTL) Inventory Average (2019 - 2026)

Castle Biosciences has reported Inventory Average for 8 years, with the latest figure at $10.5 million in Q2 2026.

• Quarterly Inventory Average rose 38.29% year-over-year to $10.5 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $10.5 million (up 38.29% YoY) and the FY2025 annual result came in at $9.2 million, up 14.38% from the prior year.
• Inventory Average improved to $10.5 million in Q2 2026 per CSTL's latest filing, from $10.4 million in the prior quarter.
• Over five years, Inventory Average peaked at $10.5 million in Q2 2026 and troughed at $2.2 million in Q1 2022.
• A 5-year average of $6.6 million and a median of $7.3 million in 2024 frame the typical range for Inventory Average.
• The sharpest annual moves came in 2023 and 2025: Inventory Average soared 94.46% in 2023, then retreated 3.87% in 2025.
• Over 5 years, Inventory Average stood at $3.9 million in 2022, then soared by 76.19% to $6.9 million in 2023, then advanced by 7.26% to $7.4 million in 2024, then gained by 28.54% to $9.5 million in 2025, then rose by 11.3% to $10.5 million in 2026.
• According to Business Quant data, Inventory Average over the past three periods registered $10.5 million, $10.4 million, and $9.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.